CTLA4 and cancer: However, we didn’t observe any significant in the IHC subgroup (HR: 1.09, 95% CI: 0.66–1.78), as well as cancer subgroup (HR: 1.26, 95% CI: 0.97–2.03) and lymphocyte subgroup divided according to CTLA-4 sources (HR: 1.42, 95% CI: 0.64–3.14).